Neurology

Vedanta raises USD 27 Million to move microbiome assets through the clinic Vedanta Biosciences raises USD 27 million in its series C round. The cash will bolster its microbiome-derived drugs pipeline. The capital will aid a phase 1/2 trial of VE416 in food allergy, a phase 2 study of VE303 in recurrent C. difficile infection and a phase 1b/2 study of VE800 in combination with Bristol-Myers Squibb’s Opdivo in advanced or metastatic cancers. The funding comes from the Bill & Melinda Gates Foundation, Bristol-Myers Squibb, Rock Springs Capital, Invesco Asset Management, Seventure Partners, and PureTech Health.  Relay Therapeutics reels in USD 400...